ZA200504238B - Thieno[3,2-b]pyridine-6-carbonitriles and thienoo[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors - Google Patents

Thieno[3,2-b]pyridine-6-carbonitriles and thienoo[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors

Info

Publication number
ZA200504238B
ZA200504238B ZA200504238A ZA200504238A ZA200504238B ZA 200504238 B ZA200504238 B ZA 200504238B ZA 200504238 A ZA200504238 A ZA 200504238A ZA 200504238 A ZA200504238 A ZA 200504238A ZA 200504238 B ZA200504238 B ZA 200504238B
Authority
ZA
South Africa
Prior art keywords
carbonitriles
pyridine
thienoo
thieno
protein kinase
Prior art date
Application number
ZA200504238A
Other languages
English (en)
Inventor
Boscheli Diane Harris
Barrios Sosa Ana Carolina
Wu Biqi
Zhang Nan
Durutlic Haris
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ZA200504238B publication Critical patent/ZA200504238B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
ZA200504238A 2002-11-25 2005-05-24 Thieno[3,2-b]pyridine-6-carbonitriles and thienoo[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors ZA200504238B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42886202P 2002-11-25 2002-11-25

Publications (1)

Publication Number Publication Date
ZA200504238B true ZA200504238B (en) 2009-09-30

Family

ID=32393469

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200504238A ZA200504238B (en) 2002-11-25 2005-05-24 Thieno[3,2-b]pyridine-6-carbonitriles and thienoo[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors

Country Status (20)

Country Link
US (1) US6987116B2 (uk)
EP (1) EP1565474A2 (uk)
JP (1) JP2006509760A (uk)
KR (1) KR20050086770A (uk)
CN (1) CN1714092A (uk)
AR (1) AR042087A1 (uk)
AU (1) AU2003290802A1 (uk)
BR (1) BR0316534A (uk)
CA (1) CA2502614A1 (uk)
CL (1) CL2003002287A1 (uk)
EC (1) ECSP055802A (uk)
MX (1) MXPA05004744A (uk)
NI (1) NI200500089A (uk)
NO (1) NO20051928L (uk)
NZ (1) NZ540104A (uk)
RU (1) RU2005120018A (uk)
TW (1) TW200412950A (uk)
UA (1) UA81000C2 (uk)
WO (1) WO2004048386A2 (uk)
ZA (1) ZA200504238B (uk)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7276519B2 (en) * 2002-11-25 2007-10-02 Wyeth Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
FR2862647B1 (fr) 2003-11-25 2008-07-04 Aventis Pharma Sa Derives de pyrazolyle, procede de preparation et intermediaires de ce procede a titre de medicaments et de compositions pharmaceutiques les renfermant
WO2006010264A1 (en) * 2004-07-30 2006-02-02 Methylgene, Inc. Inhibitors of vegf receptor and hgf receptor signaling
GB0423653D0 (en) * 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
MX2007014616A (es) 2005-05-20 2009-08-12 Methylgene Inc Inhibidores de señalizacion del receptor del factor a de crecimiento endotelial vascular y del receptor del factor de crecimiento de hepatocitos.
ES2473341T3 (es) 2005-05-20 2014-07-04 Methylgene Inc Inhibidores de la se�alizaci�n del receptor del VEGF y del receptor del HGF
WO2007035428A1 (en) 2005-09-15 2007-03-29 Bristol-Myers Squibb Company Met kinase inhibitors
PE20070619A1 (es) * 2005-09-27 2007-07-02 Wyeth Corp TIENO(2,3-b)PIRIDIN-5-CARBONITRILOS COMO INHIBIDORES DE PROTEINAS QUINASA
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
CN101522687A (zh) * 2006-01-30 2009-09-02 阿雷生物药品公司 用于癌症治疗的杂二环噻吩化合物
GB0601962D0 (en) * 2006-01-31 2006-03-15 Ucb Sa Therapeutic agents
US20100210596A1 (en) * 2006-02-01 2010-08-19 Bluestone Jeffrey A Use of aminopyrimidine compounds in the treatment of immune disorders
WO2007092153A2 (en) * 2006-02-08 2007-08-16 Wyeth Preparation of 7-alkenyl-3 quinolinecarbonitriles via a palladium mediated coupling reaction
CN101528702A (zh) * 2006-06-08 2009-09-09 阿雷生物药品公司 喹啉化合物和使用方法
BRPI0714629A2 (pt) * 2006-08-21 2013-05-07 Genentech Inc composto, composiÇço farmacÊutica, mÉtodo para inibir o crescimento celular, mÉtodo para tratar uma doenÇa inflamatària e mÉtodo para trataruma doenÇa auto-imune, lesço àsseo destrutiva, distérbios proliferativos, doenÇas infecciosas, doenÇas virais, doenÇas fibràticas ou doenÇas neurodegenerativas
MX2009001878A (es) * 2006-08-21 2009-03-03 Genentech Inc Compuestos de aza-benzofuranilo y metodos de uso.
TW200821318A (en) * 2006-09-26 2008-05-16 Wyeth Corp Process for the preparation of 4-hydroxythieno[2,3-b]pyridine-5-carbonitriles
GB0714384D0 (en) * 2007-07-23 2007-09-05 Ucb Pharma Sa theraputic agents
PL2183254T3 (pl) 2007-08-29 2017-10-31 Methylgene Inc Inhibitory aktywności białkowej kinazy tyrozynowej
US20090118276A1 (en) * 2007-11-02 2009-05-07 Wyeth Thienopyrimidines, thienopyridines, and pyrrolopyrimidines as b-raf inhibitors
WO2009093008A1 (en) * 2008-01-21 2009-07-30 Ucb Pharma S.A. Thieno-pyridine derivatives as mek inhibitors
AR070317A1 (es) * 2008-02-06 2010-03-31 Osi Pharm Inc Furo (3,2-c) piridina y tieno (3,2-c) piridinas
EP2262815A4 (en) 2008-03-05 2012-04-11 Methylgene Inc Inhibitors of protein intolerance activity
GB0811304D0 (en) * 2008-06-19 2008-07-30 Ucb Pharma Sa Therapeutic agents
EP2310373A1 (en) * 2008-07-01 2011-04-20 Genentech, Inc. Bicyclic heterocycles as mek kinase inhibitors
TW201204733A (en) 2010-06-25 2012-02-01 Kowa Co Novel condensed pyridine or condensed pyrimidine derivative, and medicinal agent comprising same
AU2013280644B2 (en) 2012-06-26 2018-08-02 Jeffrey A. BACHA Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or AHI1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
SG10201705662WA (en) 2013-01-15 2017-08-30 Incyte Corp Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
KR101468207B1 (ko) * 2013-02-14 2014-12-01 한국화학연구원 신규한 싸이에노[3,2-b]피리딜 우레아 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 유로텐신-Ⅱ 수용체 활성 관련 질환의 예방 또는 치료용 약학적 조성물
PE20160532A1 (es) 2013-08-23 2016-05-21 Incyte Corp Compuesto de carboxamida de furo y tienopiridina utiles como inhibidores de cinasas pim
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
TW201718546A (zh) 2015-10-02 2017-06-01 英塞特公司 適用作pim激酶抑制劑之雜環化合物
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
CN113195469A (zh) * 2019-02-19 2021-07-30 四川科伦博泰生物医药股份有限公司 含氮并环化合物、其制备方法及用途
US11358971B2 (en) 2019-07-03 2022-06-14 H. Lundbeck A/S Prodrugs of modulators of the NMDA receptor
US11466027B2 (en) 2019-07-03 2022-10-11 H. Lundbeck A/S Modulators of the NMDA receptor
CN114269753B (zh) * 2019-09-29 2024-03-05 四川科伦博泰生物医药股份有限公司 一种含氮并环类化合物，包含其的药物组合物，其制备方法及其用途
WO2022169866A1 (en) * 2021-02-05 2022-08-11 Ptc Therapeutics Inc. Methods for treating spinocerebellar ataxia type 3

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US45A (en) * 1836-10-11 Machine fob shelling cokm
EP0126970A3 (en) 1983-04-27 1985-11-06 Beecham Group Plc Anxiolytic and anti-depressant thienopyridine derivatives
AR004010A1 (es) * 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
CN101328186A (zh) * 1997-11-11 2008-12-24 辉瑞产品公司 用作抗癌药的噻吩并嘧啶和噻吩并吡啶衍生物
BR9914164A (pt) * 1998-09-29 2001-06-26 American Cyanamid Co Composto, método para o tratamento, inibição do crescimento de, ou erradiacação de um neoplasma, e de doença de rim policìstico, em um mamìfero em necessidade do mesmo, composição farmacêutica, e, processo para preparar um composto
JP3270834B2 (ja) * 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
GB9906566D0 (en) * 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
DE60009888T2 (de) * 1999-04-21 2005-04-21 Wyeth Corp Substituierte 3-cyano-[1.7], [1.5] und [1.8]naphthyridininhibitoren von tyrosin kinasen
AU2464601A (en) * 1999-12-29 2001-07-09 Wyeth Tricyclic protein kinase inhibitors
AR035851A1 (es) * 2000-03-28 2004-07-21 Wyeth Corp 3-cianoquinolinas, 3-ciano-1,6-naftiridinas y 3-ciano-1,7-naftiridinas como inhibidoras de proteina quinasas
EP1287001B1 (en) * 2000-06-06 2004-09-29 Pfizer Products Inc. Thiophene derivatives useful as anticancer agents
US20020004511A1 (en) * 2000-06-28 2002-01-10 Luzzio Michael Joseph Thiophene derivatives useful as anticancer agents
JP2004517059A (ja) * 2000-11-02 2004-06-10 アストラゼネカ アクチボラグ 抗腫瘍剤用の４−置換キノリン類
JP2005502643A (ja) 2001-08-10 2005-01-27 ノバルティス　アクチエンゲゼルシャフト 白血病処置のための単独またはｓｔｉ５７１と組み合せたｃ−ｓｒｃインヒビターの使用

Also Published As

Publication number Publication date
US20040138251A1 (en) 2004-07-15
WO2004048386A2 (en) 2004-06-10
TW200412950A (en) 2004-08-01
MXPA05004744A (es) 2005-08-03
NO20051928L (no) 2005-08-19
BR0316534A (pt) 2005-10-04
KR20050086770A (ko) 2005-08-30
EP1565474A2 (en) 2005-08-24
CL2003002287A1 (es) 2005-01-14
CA2502614A1 (en) 2004-06-10
RU2005120018A (ru) 2006-05-10
CN1714092A (zh) 2005-12-28
JP2006509760A (ja) 2006-03-23
NZ540104A (en) 2007-05-31
UA81000C2 (en) 2007-11-26
WO2004048386A9 (en) 2005-07-14
AU2003290802A1 (en) 2004-06-18
WO2004048386A3 (en) 2004-10-07
AR042087A1 (es) 2005-06-08
NI200500089A (es) 2006-01-11
ECSP055802A (es) 2005-08-11
US6987116B2 (en) 2006-01-17
NO20051928D0 (no) 2005-04-20

Similar Documents

Publication Publication Date Title
ZA200504238B (en) Thieno[3,2-b]pyridine-6-carbonitriles and thienoo[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
HRP20180578T1 (hr) Pirolo[2,3-b]piridin-4-il-amini i pirolo[2m3-b]pirimidin-4-il-amini kao inhibitori janus kinaze
IL170680A0 (en) 8 - SUBSTITUTED - 6,7,8,9 -TETRAHYDROPYRIMIDO [1,2-a] PYRIMIDIN - 4 - ONE DERIVATIVES
EP1653969A4 (en) PYRROLO 1,2-B PYRIDAZINE DERIVATIVES
IL172923A0 (en) PYRROLO [3,4-c] PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS
DK1635839T3 (da) Benzo[4,5]thieno[2,3-D]pyrimidin-4-oner og deres terapeutiske anvendelse
IL175221A0 (en) Akt protein kinase inhibitors
ZA200605901B (en) Pyrazolo [3,4-B] pyridine compounds, and their use as phosphodiesterase inhibitors
IL181957A0 (en) Pyrimidine-4-one derivatives as ldl-pla2 inhibitors
AU2003254053A1 (en) Pyrazolopyrimidines as protein kinase inhibitors
PL373223A1 (en) 7,8,9,10-tetrahydro-6h-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2h-pyrrolo[2,1-b]-quinazolinone derivatives
IL175813A0 (en) PYRIDO [2,3-d] PYRIMIDINE-2,4-DIAMINES AS PDE 2 INHIBITORS
HK1099302A1 (en) Pyrazolo and imidazo-pyrimidine derivatives
SI1711177T1 (sl) Derivati 1H-tieno 2,3-c pirazola, uporabni kot inhibitorji kinaze I
ZA200507192B (en) Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido [1,2-A] pyrimidin-4-one derivatives
IL154306A0 (en) Pharmaceutical compositions comprising thieno [2,3-c] pyridine derivatives and use thereof
AU2003254051A8 (en) Pyrazolopyrimidines as kinase inhibitors
PL351822A1 (en) Thienopyrimidines as phosphodiesterase inhibitors
SI1648905T1 (sl) Inhibitorji tienopiridin- in furopiridin kinaze
GB0504151D0 (en) Clopidogrel
PL370067A1 (en) 8-amino-[1,2,4]triazolo[1,5-a]pyridine-6-carboxylic acid amide
PL367185A1 (en) (pyrido/thieno)-[f]-oxazepin-5-one derivatives
IL178688A0 (en) THIENO [3,2-b] PYRIDINE-6-CARBONITRILES AS PROTEIN KINASE INHIBITORS
IL173347A0 (en) 7-SUBSTITUTED 3-NITRO-PYRAZOLO[1,5-a] PYRIMIDINES
PL350717A1 (en) Method of obtaining 4-amino 2-methyl-10h-thiene[2,3-b][1,5]benzodiazepine and method of obtaining olanzapine